Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others
Fig 3
Effects of fluoro-thalidomide on H929, AGLCL and U937 cells.
(A) Proportion of annexin V-positive cells in AGLCL cells, normal human B cells, by thalidomide, fluoro-thalidomide, (R)-fluoro-thalidomide or (S)-fluoro-thalidomide (Data are shown as mean ± SD (n = 3). ***, p < 0.001 **, p < 0.01 *, p < 0.05 vs. untreated, unless otherwise noted). (B) Proportion of annexin V-positive cells in U937 cells by thalidomide, fluoro-thalidomide, (R)-fluoro-thalidomide or (S)-fluoro-thalidomide. (C) MTT assay measuring (550 nm) the optical density of H929 cells treated with fluoro-thalidomide, (R)-fluoro-thalidomide, (S)-fluoro-thalidomide, or cytosine β-D-arabinofuranoside at a concentration of 20 μg/mL for 24 h. (D) Observation of morphological changes in H929 cells after treatment with fluoro-thalidomide, (R)-fluoro-thalidomide, (S)-fluoro-thalidomide, or cytosine β-D-arabinofuranoside at a concentration of 20 μg/mL for 24 h using Wright-Giemsa staining protocol. Apoptotic bodies (indicated by arrows) were observed after the treatment.